The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although significant findings were only reported in studies that evaluated either curcumin extract administered orally at doses ≥1000 mg/ day (Lang et al., 2015;Sadeghi et al., 2019) or bio-enhanced curcumin at doses <1000 mg/day (Banerjee et al., 2021;Masoodi et al., 2018;Sugimoto et al., 2020).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Lang et al., 2015
In the citing paper
“Studies with small sample sizes and zero events demonstrated reduced precision of estimates of treatment effect (Lang et al., 2015;Sugimoto et al., 2020).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Lang et al., 2015
In the citing paper
“Other IBD studies may not have had such restrictions (e.g., Lang et al., 2015, conducted in Israel, Hong Kong, and Cyprus, in which patients must have received at least 4 mg/day mesalamine for inclusion), adding to the clinical heterogeneity of the studies.”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Lang et al., 2015
In the citing paper
“No studies suggested significant differences in safety between curcumin, placebo, or active comparator groups, but two studies reported study withdrawal due to AEs in the turmeric group (Bundy et al., 2004;Lang et al., 2015).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Lang et al., 2015
In the citing paper
“Three other studies reported AEs or “side-effects” that were common symptoms of the underlying condition (e.g., burning sensation in the stomach and diarrhea) or were indicators of non-response to treatment (e.g., exacerbation of UC symptoms necessitating corticosteroids) (Bundy et al., 2004;Lang et al., 2015;Van Dau et al., 1998).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Lang et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis
Higgins, P. D. R., Schwartz, M., Mapili, J., Krokos, I., Leung, J., & Zimmermann, E. M. (2005) · Gut · doi:10.1136/gut.2004.056358 · Cited by 244
Research works printed but not linked: 22
- Marteau, 2005, Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study, Gut, 54, 960, 10.1136/gut.2004.060103 · DOI
- Gupta, 2013, Curcumin, a component of turmeric: from farm to pharmacy, BioFactors (Oxford, England), 39, 2, 10.1002/biof.1079 · DOI
- Midura-Kiela, 2012, Curcumin inhibits interferon-gamma signaling in colonic epithelial cells, Am J Physiol Gastrointest Liver Physiol, 302, G85, 10.1152/ajpgi.00275.2011 · DOI
- Larmonier, 2011, Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease, Inflamm Bowel Dis, 17, 503, 10.1002/ibd.21391 · DOI
- Venkataranganna, 2007, NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS, World J Gastroenterol, 13, 1103, 10.3748/wjg.v13.i7.1103 · DOI
- Sugimoto, 2002, Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice, Gastroenterology, 123, 1912, 10.1053/gast.2002.37050 · DOI · Paper page
- Hanai, 2006, Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial, Clin Gastroenterol Hepatol, 4, 1502, 10.1016/j.cgh.2006.08.008 · DOI · Paper page
- Higgins, 2005, Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?, Am J Gastroenterol, 100, 355, 10.1111/j.1572-0241.2005.40641.x · DOI
- Walmsley, 1998, A simple clinical colitis activity index, Gut, 43, 29, 10.1136/gut.43.1.29 · DOI · Paper page
- Schroeder, 1987, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study, N Engl J Med, 317, 1625, 10.1056/NEJM198712243172603 · DOI
- D'Haens, 2007, A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis, Gastroenterology, 132, 763, 10.1053/j.gastro.2006.12.038 · DOI · Paper page
- Mulder, 1996, Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis, Eur J Gastroenterol Hepatol, 8, 549, 10.1097/00042737-199606000-00010 · DOI
- Turner, 2009, A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis, Clin Gastroenterol Hepatol, 7, 1081, 10.1016/j.cgh.2009.06.024 · DOI
- Singla, 2014, Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis: a randomized, placebo-controlled, pilot study, J Crohns Colitis, 8, 208, 10.1016/j.crohns.2013.08.006 · DOI
- Singh, 1995, Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected], J Biol Chem, 270, 24995, 10.1074/jbc.270.42.24995 · DOI
- Chen, 2008, Anti-inflammatory activity of curcumin in macrophages stimulated by lipopolysaccharides from Porphyromonas gingivalis, Pharmacology, 82, 264, 10.1159/000161127 · DOI
- Chan, 1995, Inhibition of tumor necrosis factor by curcumin, a phytochemical, Biochem Pharmacol, 49, 1551, 10.1016/0006-2952(95)00171-U · DOI
- Salh, 2003, Curcumin attenuates DNB-induced murine colitis, Am J Physiol Gastrointest Liver Physiol, 285, G235, 10.1152/ajpgi.00449.2002 · DOI
- Larmonier, 2008, Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection, Am J Physiol Gastrointest Liver Physiol, 295, G1079, 10.1152/ajpgi.90365.2008 · DOI
- Usharani, 2008, Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study, Drugs R D, 9, 243, 10.2165/00126839-200809040-00004 · DOI
- Baum, 2008, Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease, J Clin Psychopharmacol, 28, 110, 10.1097/jcp.0b013e318160862c · DOI · Paper page
- Cruz-Correa, 2006, Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis, Clin Gastroenterol Hepatol, 4, 1035, 10.1016/j.cgh.2006.03.020 · DOI · Paper page
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders
Thavorn, K., Wolfe, D., Faust, L., Shorr, R., Akkawi, M., Isaranuwatchai, W., Klinger, C., Chai‐Adisaksopa, C., Tanvejsilp, P., Nochaiwong, S., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8189 · Cited by 11
Metadata
- Authors
- Lang, A., Salomon, N., Wu, J. C. Y., Kopylov, U., Lahat, A., Har-Noy, O., Ching, J. Y. L., Cheong, P. K., Avidan, B., Gamus, D., Kaimakliotis, I., Eliakim, R., Ng, S. C., & Ben-Horin, S.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 13
- Issue
- 8
- Pages
- 1444-1449.e1
- ISSN
- 1542-3565
- Cited by
- 343
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
